Allergy Testing Access Act of 2021
The source supplies the latest action, but no lifecycle stage.
Latest action (25 Jun 2021): Referred to the Subcommittee on Health.
What this bill does
H.R. 4114, the Allergy Testing Access Act of 2021, aims to ensure that two types of allergy tests receive equal coverage under Medicare and Medicaid. Specifically, the bill would require that in vitro specific IgE tests (blood tests) and percutaneous tests (skin tests) be treated the same in terms of medical necessity requirements, limits on how often they can be performed, and limits on the number of allergens tested annually.
This legislation affects individuals covered by Medicare and Medicaid who may need allergy testing. The bill intends to make both blood and skin allergy tests equally accessible to patients and their doctors, based on findings that these tests are considered equivalent in accuracy by health organizations.
The bill was introduced in the House of Representatives in June 2021. It has been referred to two committees for consideration. If passed by Congress and signed into law, the changes related to Medicare coverage would generally take effect on January 1, 2022. For Medicaid, the changes would also generally apply from January 1, 2022, with some flexibility for states that require legislative action to comply.
Plain-English summary generated by Bill100 AI from the official record. Always verify against the source below.
Official summary
Allergy Testing Access Act of 2021
This bill requires equal coverage of two types of allergy tests under Medicaid and Medicare.
Specifically, in vitro specific IgE tests (blood tests) and percutaneous tests (skin tests) must be treated equally with respect to (1) medical necessity or other coverage requirements, (2) frequency limits, and (3) allergen unit limits.
Timeline
25 Jun 2021
Referred to the Subcommittee on Health.
Common questions
- What does H.R. 4114 do?
- H.R. 4114, the Allergy Testing Access Act of 2021, aims to ensure that two types of allergy tests receive equal coverage under Medicare and Medicaid. Specifically, the bill would require that in vitro specific IgE tests (blood tests) and percutaneous tests (skin tests) be treated the same in terms of medical necessity requirements, limits on how often they can be performed, and limits on the number of allergens tested annually. This legislation affects individuals covered by Medicare and Medicaid who may need allergy testing. The bill intends to make both blood and skin allergy tests equally accessible to patients and their doctors, based on findings that these tests are considered equivalent in accuracy by health organizations. The bill was introduced in the House of Representatives in June 2021. It has been referred to two committees for consideration. If passed by Congress and signed into law, the changes related to Medicare coverage would generally take effect on January 1, 2022. For Medicaid, the changes would also generally apply from January 1, 2022, with some flexibility for states that require legislative action to comply.
- Has H.R. 4114 become law?
- The source does not supply a confirmed lifecycle stage for H.R. 4114. Check the latest action and official source below.
- Who sponsored H.R. 4114?
- H.R. 4114 was sponsored by Rep. Clarke, Yvette D. [D-NY-9] (D-NY), with 27 cosponsors.
- What's the latest action on H.R. 4114?
- Referred to the Subcommittee on Health. (25 Jun 2021).
Related bills in Health
Choices for Increased Mobility Act of 2026
Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026
Access to Medical Supplies Act
Lower Premiums, Faster Payments Act
More bills from Rep. Clarke, Yvette D. [D-NY-9]
Expressing support for the recognition of October 2026, as "World Menopause Awareness Month" and for global awareness and access to care during menopausal transition and post-menopause.
American Renewable Energy Act of 2026
Interagency Council on Affordable Housing Act of 2026
Artificial Intelligence Civil Rights Act of 2025
Bill100 mirrors the public U.S. legislative record from Congress.gov and GovTrack and adds plain-English AI summaries. It is an information tool, not legal, compliance or lobbying advice, and it is not affiliated with the U.S. Congress or any government agency. AI summaries can simplify or omit detail — every bill links to the official source; verify there before you rely on it.